$0.94
-0.02 (-2.55%)
Open$0.96
Previous Close$0.96
Day High$0.98
Day Low$0.88
52W High$2.35
52W Low$0.36
Volume—
Avg Volume6.56M
Market Cap202.89M
P/E Ratio—
EPS$-0.47
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+3,766.3% upside
Current
$0.94
$0.94
Target
$36.15
$36.15
$26.32
$36.15 avg
$48.95
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 59.14M | 52.95M | 62.98M |
| Net Income | 4.93M | 4.47M | 5.16M |
| Profit Margin | 8.3% | 8.4% | 8.2% |
| EBITDA | 5.59M | 4.86M | 6.72M |
| Free Cash Flow | 3.58M | 3.18M | 3.67M |
| Rev Growth | +23.4% | +5.7% | +6.5% |
| Debt/Equity | 0.46 | 0.42 | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |